Wentian Y. Wang

State Key Laboratory Of Experimental Hematology, Chinese Academy Of Medical Sciences & Peking Union Medical College, Tianjin 300020
Tianjin, 301600, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 36 publications

Efficacy and safety of a JAK1 inhibitor for relapsed/refractory large granular lymphocytic leukemia

Efficacy and safety of a JAK1 inhibitor for relapsed/refractory large granular lymphocytic leukemia

Journal: Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi

Published: September 07, 2026

Erratum to: "Multilevel defects in the hematopoietic niche in essential thrombocythemia".

Erratum to: "Multilevel defects in the hematopoietic niche in essential thrombocythemia".

Journal: Haematologica

Published: June 01, 2026

Treatment practice and outcomes in 125 patients with autoimmune hemolytic anemia: a single-center retrospective analysis

Treatment practice and outcomes in 125 patients with autoimmune hemolytic anemia: a single-center retrospective analysis

Journal: Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi

Published: April 16, 2026

Daratumumab in patients with immune thrombocytopenia: a single-center, open-label, phase 2 trial.

Daratumumab in patients with immune thrombocytopenia: a single-center, open-label, phase 2 trial.

Journal: EClinicalMedicine

Published: November 05, 2025

Anti-CD38 monoclonal antibody CM313 for primary immune thrombocytopenia: multicentre, randomised, placebo controlled, phase 2 trial.

Anti-CD38 monoclonal antibody CM313 for primary immune thrombocytopenia: multicentre, randomised, placebo controlled, phase 2 trial.

Journal: BMJ (Clinical research ed.)

Published: October 21, 2025

Phase 1 pilot study for hemophilia-A: AAV8 vector with prophylactic tacrolimus-glucocorticoid achieves therapeutic FVIII activity.

Phase 1 pilot study for hemophilia-A: AAV8 vector with prophylactic tacrolimus-glucocorticoid achieves therapeutic FVIII activity.

Journal: Signal transduction and targeted therapy

Published: September 26, 2025

IFNα2b modulates anti-tumor immune responses involving STAT3-associated dendritic cell dysfunction in JAK2v617f-positive myeloproliferative neoplasms.

IFNα2b modulates anti-tumor immune responses involving STAT3-associated dendritic cell dysfunction in JAK2v617f-positive myeloproliferative neoplasms.

Journal: Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy

Published: August 25, 2025

Low-dose oral nicotinamide mononucleotide for immune thrombocytopenia: a phase 1/2 trial.

Low-dose oral nicotinamide mononucleotide for immune thrombocytopenia: a phase 1/2 trial.

Journal: Nature medicine

Published: July 25, 2025

Bone marrow proteomic profiling reveals TMEM109 as a biomarker for relapse in thrombotic thrombocytopenic purpura.

Bone marrow proteomic profiling reveals TMEM109 as a biomarker for relapse in thrombotic thrombocytopenic purpura.

Journal: Journal of thrombosis and haemostasis : JTH

Published: July 24, 2025

Hypoxia and HIF-1 inhibition enhance lentiviral transduction efficiency: a novel strategy for gene delivery optimization.

Hypoxia and HIF-1 inhibition enhance lentiviral transduction efficiency: a novel strategy for gene delivery optimization.

Journal: BMC biotechnology

Published: March 07, 2025

DNp73 enhances tumor progression and immune evasion in multiple myeloma by targeting the MYC and MYCN pathways.

DNp73 enhances tumor progression and immune evasion in multiple myeloma by targeting the MYC and MYCN pathways.

Journal: Frontiers in immunology

Published: July 25, 2024

A Novel Anti-CD38 Monoclonal Antibody for Treating Immune Thrombocytopenia.

A Novel Anti-CD38 Monoclonal Antibody for Treating Immune Thrombocytopenia.

Journal: The New England journal of medicine

Published: June 20, 2024

Showing 1-12 of 36

Last Updated: 09/26/2026